Supplementary table 1.docx: A Phase I trial of talazoparib in patients witha dvanced hematologic malignancies
Supplementary Figure 1. Dose linearity and
proportionality in plasma following multiple doses of talazoparib.
Supplementary Table 1. Patient disposition by dose level and diagnosis (safety population).†
Supplementary Table 2. Exposure to talazoparib (safety population).